ATE353666T1 - Verwendung von aktiviertem gerinnungsfaktor vii zur behandlung von durch thrombolytische therapie-induzierten wichtigen blutungen - Google Patents

Verwendung von aktiviertem gerinnungsfaktor vii zur behandlung von durch thrombolytische therapie-induzierten wichtigen blutungen

Info

Publication number
ATE353666T1
ATE353666T1 AT01995705T AT01995705T ATE353666T1 AT E353666 T1 ATE353666 T1 AT E353666T1 AT 01995705 T AT01995705 T AT 01995705T AT 01995705 T AT01995705 T AT 01995705T AT E353666 T1 ATE353666 T1 AT E353666T1
Authority
AT
Austria
Prior art keywords
factor vii
treatment
clotting factor
thrombolytic therapy
activated clotting
Prior art date
Application number
AT01995705T
Other languages
English (en)
Inventor
Cord Skamira
Jean Marie Stassen
Gerhard Heusel
Wolfgang Wienen
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Application granted granted Critical
Publication of ATE353666T1 publication Critical patent/ATE353666T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT01995705T 2000-12-21 2001-12-20 Verwendung von aktiviertem gerinnungsfaktor vii zur behandlung von durch thrombolytische therapie-induzierten wichtigen blutungen ATE353666T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00128252A EP1216709A1 (de) 2000-12-21 2000-12-21 Verwendung von aktiviertem Gerinnungsfaktor VII zur Behandlung von durch thrombolytische Therapie-induzierten wichtigen Blutungen

Publications (1)

Publication Number Publication Date
ATE353666T1 true ATE353666T1 (de) 2007-03-15

Family

ID=8170769

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01995705T ATE353666T1 (de) 2000-12-21 2001-12-20 Verwendung von aktiviertem gerinnungsfaktor vii zur behandlung von durch thrombolytische therapie-induzierten wichtigen blutungen

Country Status (25)

Country Link
US (2) US20040087502A1 (de)
EP (2) EP1216709A1 (de)
JP (1) JP2004516273A (de)
KR (1) KR20030063454A (de)
CN (1) CN1482919A (de)
AT (1) ATE353666T1 (de)
AU (2) AU2638602A (de)
BR (1) BR0116151A (de)
CA (1) CA2431986A1 (de)
CY (1) CY1106363T1 (de)
CZ (1) CZ300670B6 (de)
DE (1) DE60126650T2 (de)
DK (1) DK1343523T3 (de)
EC (1) ECSP034647A (de)
ES (1) ES2280429T3 (de)
HU (1) HUP0302574A3 (de)
IL (1) IL155886A0 (de)
MX (1) MXPA03005641A (de)
NZ (1) NZ549850A (de)
PL (1) PL205878B1 (de)
PT (1) PT1343523E (de)
RU (1) RU2286796C2 (de)
SI (1) SI1343523T1 (de)
WO (1) WO2002049665A2 (de)
ZA (1) ZA200304140B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2570330A1 (en) * 2004-06-21 2005-12-29 Novo Nordisk Health Care A/S Use of factor viia or factor viia equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage (ich)
RU2396086C2 (ru) * 2004-09-10 2010-08-10 Фармаоригин Апс Способы лечения трахеального, бронхиального или альвеолярного кровотечения или кровохарканья
EP1906993A2 (de) * 2005-07-15 2008-04-09 Novo Nordisk Health Care AG Verwendung von faktor viia oder faktor viia-äquivalenten zur prävention oder abschwächung von hämorrhagiewachstum und/oder ödembildung nach interzerebraler blutung (ich) bei patienten unter einer anti-thrombozyten-therapie
CN101918025A (zh) 2008-01-18 2010-12-15 诺沃-诺迪斯克保健股份有限公司 因子Ⅶa或因子Ⅶa等同物用于防止或减弱选择的脑内出血患者亚群在脑内出血(ICH)后出血增多和/或水肿形成的用途
RU2552339C1 (ru) * 2014-02-19 2015-06-10 Общество с ограниченной ответственностью фирма "Технология-Стандарт" Способ профилактики кровотечений, вызванных применением стрептокиназы, в эксперименте

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4382082A (en) * 1980-12-18 1983-05-03 Uop Inc. Recovery of cobalt values by absorption from ammoniacal solution
ZA862768B (en) * 1985-04-17 1986-12-30 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5374617A (en) * 1992-05-13 1994-12-20 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with FVIIa
US5846517A (en) * 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
WO1998058661A1 (en) * 1997-06-23 1998-12-30 Novo Nordisk A/S Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function

Also Published As

Publication number Publication date
HUP0302574A2 (hu) 2003-10-28
RU2286796C2 (ru) 2006-11-10
NZ549850A (en) 2008-04-30
CA2431986A1 (en) 2002-06-27
PT1343523E (pt) 2007-03-30
BR0116151A (pt) 2003-10-21
EP1343523A2 (de) 2003-09-17
HUP0302574A3 (en) 2010-01-28
US20040087502A1 (en) 2004-05-06
DE60126650T2 (de) 2007-10-31
KR20030063454A (ko) 2003-07-28
MXPA03005641A (es) 2004-12-03
IL155886A0 (en) 2003-12-23
EP1343523B1 (de) 2007-02-14
ECSP034647A (es) 2003-07-25
WO2002049665A2 (en) 2002-06-27
EP1216709A1 (de) 2002-06-26
PL361855A1 (en) 2004-10-04
DE60126650D1 (de) 2007-03-29
SI1343523T1 (sl) 2007-04-30
DK1343523T3 (da) 2007-04-10
US20080286259A1 (en) 2008-11-20
WO2002049665A3 (en) 2002-09-26
PL205878B1 (pl) 2010-06-30
AU2638602A (en) 2002-07-01
CY1106363T1 (el) 2011-10-12
AU2002226386B2 (en) 2005-12-22
JP2004516273A (ja) 2004-06-03
CN1482919A (zh) 2004-03-17
ES2280429T3 (es) 2007-09-16
ZA200304140B (en) 2004-04-22
CZ20031743A3 (cs) 2003-11-12
CZ300670B6 (cs) 2009-07-15
RU2003122362A (ru) 2005-02-10

Similar Documents

Publication Publication Date Title
ATE552842T1 (de) Verwendung von plasminogen zur wundheilung
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
ATE323071T1 (de) Substituierte phenolderivate und deren salze als hemmstoffe von koagulations faktor x
BR0110659A (pt) Composição farmacêutica, kit, uso de um fator viia em combinação com um fator, xiii, e, métodos para intensificação da formação de coágulo de fibrina em um indivìduo e para tratar de episódios de hemorragia em um indivìduo
DE602004018338D1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
DE69022150D1 (de) Neue Peptidasen und Isomerasen-Inhibitoren.
PT816376E (pt) Inibidores de trombina como agentes anticoagulantes
DK1414494T3 (da) Hæmmende antistoffer af HER3-aktivitet
ATE444086T1 (de) Therapeutische zusammensetzungen und verfahren zur behandlung von periodontitis mit entzündunshemmenden mitteln
BR0011295A (pt) Aril e heteroaril pirazinonas policìclicas substituìdas úteis para inibição seletiva de cascata de coagulação
DE60126650D1 (de) Verwendung von aktiviertem gerinnungsfaktor vii zur behandlung von durch thrombolytische therapie-induzierten wichtigen blutungen
ATE402694T1 (de) Verwendung von 1-phenyl-3-dimethylamino-propan- verbindungen zur therapie der harninkontinenz
DE60128009D1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE60111620D1 (de) Aktiviertes protein c zur behandlung von pankreatitis
PT1268463E (pt) 4-pironas substituidas com arilo e heteroarilo policiclicos uteis para a inibicao selectiva da cascata de coagulacao
ATE430578T1 (de) Faktor viii oder von willebrand faktor zur behandlung von thrombopathie assoziierenden hämorrhagischen erkrankungen
DE60128084D1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
ATE315387T1 (de) Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz
ATE314066T1 (de) Verwendung von buprenorphin zur therapie der harninkontinenz
ATE337790T1 (de) Verwendung von cortisol-sequestriermitteln zur behandlung von hypercortisolaemie-verwandten erkrankungen
ATE311901T1 (de) Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten
ATE415165T1 (de) Kombinierte tumortherapie auf der basis von distamycin-acryloyl derivate und antimetabolische mitteln
ATE288263T1 (de) Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis)
ATE360437T1 (de) Verwendung des blutgerinnungsfaktors xiii für die behandlung der hämophilie a
ATE336261T1 (de) Blutgerinnungsfaktor xiii zur behandlung von plättchenfunktionsstörungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1343523

Country of ref document: EP

REN Ceased due to non-payment of the annual fee